Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy
Treatment (Paclitaxel and Carboplatin) in Stage III-IV Uterine Cancer
How well does the combination of pembrolizumab, paclitaxel, and carboplatin work compared
with paclitaxel and carboplatin alone in treating patients with uterine (endometrial)
cancer that is stage III, IV, or has come back (recurrent).
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase III trial studies how well the combination of pembrolizumab, paclitaxel,
and carboplatin, works compared with paclitaxel and carboplatin alone in treating
patients with endometrial cancer that is stage III, IV, or has come back (recurrent).
Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's
immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part
of the usual treatment approach for this type of cancer. This study aims to assess
if adding immunotherapy to these drugs is better or worse than the usual approach
for treatment of this cancer.
Study Reference #: CGYE19140
Lead Researcher (Principal Investigator)
Lead Researcher: Richard Moore
Study Contact InformationStudy Coordinator: Barbara Kavinsky
Phone: (585) 273-3602
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search